Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis
| Author | Mohammad Ehsan Bayatpoor | en |
| Author | Mohammad Hossein Khosravi | en |
| Author | Heidar Sharafi | en |
| Author | Mohammad Saeid Rezaee-Zavareh | en |
| Author | Bita Behnava | en |
| Author | Seyed Moayed Alavian | en |
| Orcid | Heidar Sharafi [0000-0001-9177-9117] | en |
| Orcid | Seyed Moayed Alavian [0000-0002-4443-6602] | en |
| Issued Date | 2019-02-28 | en |
| Abstract | Background: Direct-acting antiviral agents (DAAs) have changed the treatment landscape of hepatitis C virus (HCV) infection. Sofosbuvir (SOF), as a DAA inhibiting HCV NS5B polymerase, has found a remarkable contribution to the treatment regimens of HCV genotype-2 (HCV-2) and -3 infections. Objectives: In this meta-analysis, we aimed to evaluate the efficacy of the combination of SOF and Ribavirin (RBV) with or without pegylated-interferon (PegIFN) in the treatment of HCV-2 and -3 infections. Methods: In this meta-analysis, we searched electronic databases including PubMed, Scopus, ScienceDirect, and Web of Science using appropriate and relevant keywords. Based on the results of the heterogeneity test (chi-squared and I-squared), fixed- or random-effects models were used to calculate the pooled sustained virological response (SVR) rates. Results: After removing duplicates and screening of 1408 articles, 16 studies were included in the quantitative synthesis. The pooled SVR rates calculated for the treatment of patients suffering HCV-2 infection were 92% (95% CI: 87% - 96%) using the SOF + RBV regimen for 12 weeks and 95% (95% CI: 85% - 100%) using the SOF + RBV + PegIFN regimen for 12 weeks. The pooled SVR calculated for the treatment of patients suffering HCV-3 infection was 55% (95% CI: 44% - 66%) using the SOF + RBV regimen for 12 weeks, 81% (95% CI: 72% - 88%) using the SOF + RBV regimen for 24 weeks, and 93% (95% CI: 85% - 99%) using the SOF + RBV + PegIFN regimen for 12 weeks. Conclusions: The combination of SOF and RBV with or without PegIFN for 12 weeks is highly efficacious (> 90%) for the treatment of patients with HCV-2 infection. However, for the treatment of patients with HCV-3 infection only 12 weeks of SOF + PegIFN + RBV would result in > 90% treatment success. | en |
| DOI | https://doi.org/10.5812/archcid.79465 | en |
| Keyword | Hepatitis C | en |
| Keyword | Sofosbuvir | en |
| Keyword | Ribavirin | en |
| Keyword | Pegylated-Interferon | en |
| Keyword | Meta-Analysis | en |
| Publisher | Brieflands | en |
| Title | Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections: A Systematic Review and Meta-Analysis | en |
| Type | Review Article | en |